The Journal of ExtraCorporeal Technology No 56-3 | Page 16

B . Ali et al .: J Extra Corpor Technol 2024 , 56 , 84 – 93 91
Table 3 . Intraoperative and postoperative clinical characteristics .
Control group ( rdNC )
Group A ( rldNCS )
Group B ( prdNCS )
p-value
n = 40
n = 40
n = 40
Bypass time ( min )
68.5 ( 60 – 80 )
68.5 ( 60 – 86.75 )
70 ( 65 – 75.75 )
0.824
Clamp time ( min )
42.5 ( 35.75 – 47.75 )
41.5 ( 38.25 – 54.75 )
44.5 ( 38 – 49.25 )
0.796
Post clamp off VF . DC
14 ( 35 )
11 ( 27.3 )
12 ( 30 )
0.761
Total grafts
4 ( 3.25 – 4 )
4 ( 4 – 4 )
4 ( 3 – 4 )
0.536
CK-MB ( UL �1 ) Baseline
12.22 ± 7.26
10.35 ± 7.18
12.82 ± 6.71
Time = 0.344
2 h
13.22 ± 7.09
11.52 ± 7.17
15.30 ± 7.10
Time Gp = 0.787
12 h
12.05 ± 7.27
11.81 ± 7.29
12.90 ± 7.59
Group = 0.078
24 h
12.61 ± 6.83
11.86 ± 7.32
12.37 ± 7.03
Trop T ( ngmL �1 ) Baseline
0.106 ± 0.055
0.108 ± 0.060
0.105 ± 0.063
Time = 0.034 *
2 h
0.128 ± 0.067
0.132 ± 0.060
0.119 ± 0.063
Time Gp = 0.759
12 h
0.115 ± 0.066
0.133 ± 0.074
0.130 ± 0.066
Group = 0.143
24 h
0.107 ± 0.076
0.126 ± 0.077
0.095 ± 0.069
Trop I ( ngmL �1 ) Baseline
0.016 ± 0.009
0.020 ± 0.016
0.012 ± 0.012
Time = 0.609
2 h
0.015 ± 0.011
0.019 ± 0.015
0.014 ± 0.014
Time Gp = 0.444
12 h
0.018 ± 0.009
0.020 ± 0.009
0.015 ± 0.014
Group = 0.311
24 h
0.019 ± 0.010
0.017 ± 0.010
0.015 ± 0.015
Lactate ( mgdL �1 ) Baseline
10.42 ± 5.10
11.73 ± 4.89
11.38 ± 4.95
Time = < 0.001 *
2 h
14.65 ± 6.11
14.03 ± 5.27
12.52 ± 4.60
Time Gp = 0.064
12 h
15.54 ± 5.61
12.08 ± 5.07
13.30 ± 4.67
Group = 0.129
24 h
12.11 ± 4.30
11.65 ± 4.07
11.15 ± 4.02
Post operative AFL
2 ( 5 )
3 ( 7.5 )
4 ( 10 )
0.908
Post operative AF
4 ( 10 )
5 ( 12.5 )
4 ( 10 )
> 0.999
Ventilation support ( h )
5.7 ( 4.5 – 6.5 )
5.5 ( 4.1 – 6.5 )
5.7 ( 4.5 – 7 )
0.580
ICU stay ( h )
64 ( 43.23 – 85.25 )
63.5 ( 40.50 – 75.75 )
52 ( 45.50 – 69.50 )
0.484
CK-MB ( Creatine Kinase-Myoglobin Binding ), Trop T ( Troponin T ), Trop I ( Troponin I ), VF . DC ( Ventricular Fibrillation needing Direct Current Cardioversion ), AFL ( Atrial Flutter ), AF ( Atrial Fibrillation ), ICU ( Intensive Care Unit ). * p < 0.05 .
et al . [ 9 ] conducted a review of articles regarding the use of single-dose Bretschneider cardioplegia and single-dose del Nido cardioplegia in adult cardiac surgery . Their findings showed that del Nido cardioplegia was a superior and safer technique for myocardial protection , resulting in reduced aortic cross-clamp duration , cardiopulmonary bypass time , and required cardioplegia solution volume . This technique also exhibited benefits for many organs and cardiac biochemical parameters .
Our study used a modified version of the del Nido cardioplegia solution as a control group in our setups , which showed no major complications in the past . However , our research found no significant differences in myocardial protection between using normal saline-based , Ringer lactate-based , or plain Ringer-based modified del Nido cardioplegia , alongside other intraoperative and postoperative factors .
Regardless of statistical significance , there were some differences observed , The levels of CK-MB were higher in the plain Ringer-based del Nido cardioplegia group , while Troponin T and Troponin I were higher in the Ringer lactate-based del Nido cardioplegia group , and lactate was higher in the normal saline-based group . Interestingly , the bypass time , clamp time , frequency of atrial flutter , and mechanical ventilation support were higher in the plain Ringer-based del Nido cardioplegia group . After clamping off , VF needing DC shock and ICU stay were higher in the normal saline-based del Nido cardioplegia group , and the frequency of atrial fibrillation was higher in the Ringer lactate-based group . However , since the primary outcome values for all groups were within the normal range , we cannot claim one solution is superior to the others based on these differences . Similarly , based on the various outcomes observed , we cannot confirm our hypothesis that Ringer lactate-based del Nido cardioplegia will prove to be more efficient than the other two groups , in terms of cardiac markers .
Therefore , we concluded that all three solutions , including normal saline , Ringer lactate , and plain Ringer , can serve as a baseline solution for modified del Nido cardioplegia if the Plasma Lyte A solution is unavailable .
Limitation
Our study had several limitations , but the major one was the use of normal saline as the baseline solution for routine del Nido cardioplegia and considering this modified version as a control in our study . Our results may not be generalizable to other countries with original cardioplegia . Additionally , our inclusion criteria only covered low-risk elective isolated CABG surgeries .